Roivant Sciences

ROIVPhase 2

Founded 2019roivant.com

Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.

Market Cap

$19.8B

Founded

2019

ROIV · Stock Price

USD 27.70+22.72 (+456.22%)

Historical price data

AI Company Overview

Technology Platform

Roivant operates through a unique 'Vant' model, creating focused subsidiary companies that function as independent biotech entities with specialized management teams, aligned incentives, and entrepreneurial focus while benefiting from centralized capital allocation and shared resources.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
Gimsilumab + Placebo	COVID-19	Phase 2
Ketamine + Placebo	Autism Spectrum Disorder	Phase 1

Funding History

Total raised: $1.5B

PIPE$200MViking Global InvestorsMay 15, 2021

Series B$1.1BSoftBank Vision FundJul 15, 2017

Series A$200MViking Global InvestorsJan 15, 2015

Opportunities

Roivant has multiple near-term value catalysts including FDA filing for brepocitinib in dermatomyositis, several Phase 3 readouts for IMVT-1402 across autoimmune conditions, and potential expansion into additional indications.

The company's proven execution track record and diversified pipeline position it well for continued growth and partnership opportunities.

Risk Factors

Key risks include clinical development failures across multiple programs, regulatory delays or rejections, intense competition in the JAK inhibitor space, and the complexity of managing multiple subsidiary companies.

The company's success depends heavily on continued positive clinical outcomes and successful commercialization execution.

Competitive Landscape

Roivant competes against large pharmaceutical companies and specialized biotech firms in autoimmune and rare diseases, with key differentiators including its unique Vant organizational model, proven Phase 3 execution track record, and diversified pipeline reducing concentration risk. The company's focus on rare autoimmune conditions provides opportunities in areas with limited treatment options and high unmet medical need.

Publications

Patents

Pipeline